Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

AegirBio receives second milestone payment under RadX NIH

Lund June 11, 2024 – AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today the company has received its second milestone-based payment of USD 180,829 under the RadX NIH program. In May, AegirBio received the first milestone payment of USD 148,026 under this agreement. The milestones validate AegirBio’s unwavering dedication to pioneering research and development.

"At AegirBio, we are committed to pushing the boundaries of innovation and fostering positive change in healthcare. The payments from RadX NIH reflect the tireless efforts of our team," said Marco Witteveen, CEO of AegirBio.

As we celebrate this milestone, our commitment to advancing with RadX remains unwavering. With ongoing support from initiatives like RadX NIH and the expertise of our talented team, we are positioned to drive significant progress and make meaningful contributions to the field.

For additional information, please contact:

Marco Witteveen, CEO, AegirBio AB
Email: ir@aegirbio.com

About AegirBio:

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se

Datum 2024-06-11, kl 09:15
Källa MFN